Key facts
- EntoZyme’s last known valuation is $5.2M (Sep 2025).
- It has raised $2.1M; the latest was Early Stage VC ($2.0M) in Sep 2025.
- Notable investors include Main Sequence Ventures, Macquarie University, UNSW Founders, UNSW Innovation Community.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for EntoZyme
- ·The full record, as it builds
Funding rounds
No funding rounds for EntoZyme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EntoZyme
Developer of genetic engineering techniques designed to process various organic waste streams and produce valuable enzymes and bioactive compounds. The company develops novel strains of BSF using platform genetic engineering technologies to improve its ability to convert organic waste streams, to produce customized feed for livestock and aquaculture, and to produce high-value bioproducts for the agriculture, cosmetics, transport, and pharma industries, enabling users to get sustainable waste valorization and high-value bioproducts, ensuring a cleaner, greener planet.
- Sector
- Healthcare
- HQ
- Maroubra, Australia
- Employees
- 9
- Website
- entozyme.com/
- Ownership
- Privately Held (backing)
EntoZyme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EntoZyme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EntoZyme in its N-PORT filings yet. We sweep new filings monthly.